|
Market Closed -
NYSE
23:02:20 01/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 259.99 USD | +1.39% |
|
-2.18% | +13.79% |
| 09-01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 08-27 | AbbVie Seeks EU Approval for Subcutaneous Skyrizi Induction in Crohn's Disease | MT |
| Market Cap | 459B 396B 373B 340B 639B 43,603B 642B 4,407B 1,715B 22,180B 1,725B 1,688B 73,545B | P/E 2026 * |
33.2x | P/E 2027 * | 24.5x |
|---|---|---|---|---|---|
| Enterprise Value | 520B 448B 422B 384B 723B 49,344B 727B 4,987B 1,941B 25,100B 1,952B 1,910B 83,228B | EV / Sales 2026 * |
7.69x | EV / Sales 2027 * | 6.95x |
| Free-Float |
95.71% | Yield 2026 * |
2.64% | Yield 2027 * | 2.77% |
Last Transcript : AbbVie Inc.
| 1 day | +1.39% | ||
| 1 week | -2.18% | ||
| Current month | +1.39% | ||
| 1 month | +3.61% | ||
| 3 months | +22.10% | ||
| 6 months | +12.03% | ||
| Current year | +13.79% |
| 1 week | 252.33 |  | 262.5 |
| 1 month | 241.2 | | 266.96 |
| Current year | 190.75 | | 267.47 |
| 1 year | 190.75 | | 267.47 |
| 3 years | 135.85 | | 267.47 |
| 5 years | 105.56 | | 267.47 |
| 10 years | 55.06 | | 267.47 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 23/06/2022 |
Linda Ray
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 74 | 01/01/2013 |
Ed Rapp
BRD | Director/Board Member | 69 | 01/01/2013 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/14/26 A | Exercice | Executive/Senior Manager | 98,130 | 0.0056% | ||
| 6/30/26 A | Free | Director | 62 | 0.0000% | ||
| 6/30/26 A | Free | Director | 134 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.39% | -2.18% | +23.57% | +75.43% | 459B | |
| +0.28% | -5.97% | +58.34% | +108.22% | 1,034B | |
| +2.01% | -0.71% | +53.07% | +68.99% | 654B | |
| +0.88% | -4.78% | +33.85% | +36.11% | 343B | |
| -0.58% | +2.41% | +28.70% | +46.29% | 307B | |
| -0.43% | -2.50% | +0.20% | +11.58% | 251B | |
| +1.92% | -0.93% | +52.28% | +70.67% | 237B | |
| +0.58% | -2.98% | -17.46% | -54.86% | 202B | |
| +2.45% | +0.77% | +32.71% | +95.59% | 186B | |
| +0.32% | -0.07% | +15.31% | -20.21% | 163B | |
| Average | +1.05% | -2.60% | +28.06% | +43.78% | 383.43B | |
| Weighted average by Cap. | +1.24% | -3.18% | +37.48% | +62.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 67.58B 58.3B 54.84B 49.96B 93.95B 6,414B 94.46B 648B 252B 3,263B 254B 248B 10,819B | 73.52B 63.42B 59.65B 54.35B 102B 6,977B 103B 705B 274B 3,549B 276B 270B 11,769B |
| Net income | 13.86B 11.96B 11.25B 10.25B 19.27B 1,316B 19.37B 133B 51.75B 669B 52.04B 50.92B 2,219B | 18.91B 16.32B 15.35B 13.98B 26.29B 1,795B 26.43B 181B 70.62B 913B 71.01B 69.47B 3,028B |
| Net Debt | 60.49B 52.18B 49.08B 44.72B 84.09B 5,741B 84.54B 580B 226B 2,920B 227B 222B 9,683B | 51.66B 44.56B 41.92B 38.19B 71.81B 4,903B 72.2B 496B 193B 2,494B 194B 190B 8,270B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/09/26 | $259.99 | +1.39% | 3,866,739 |
| 31/08/26 | $256.42 | +0.37% | 4,315,487 |
| 28/08/26 | $255.48 | -1.03% | 3,224,862 |
| 27/08/26 | $258.15 | -1.81% | 4,764,797 |
| 26/08/26 | $262.90 | -1.09% | 3,308,871 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
